Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Primary Non-metastatic Breast Cancer|Who Remain Disease-free
Interventions: DRUG: Everolimus|DRUG: Placebo
Sponsor: UNICANCER
Collaborators: Ministry of Health, France